GPR120 suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy

• Main Authors: Santhosh Satapati, Ying Qian, Margaret S. Wu, Aleksandr Petrov, Ge Dai, Sheng-ping Wang, Yonghua Zhu, Xiaolan Shen, Eric S. Muise, Ying Chen, Emanuel Zycband, Adam Weinglass, Jerry Di Salvo, John S. Debenham, Jason M. Cox, Ping Lan, Vinit Shah, Stephen F. Previs, Mark Erion, David E. Kelley, Liangsu Wang, Andrew D. Howard, Jin Shang
• Format: Article
• Language: English
• Published: Elsevier 2017-08-01
• Series: Journal of Lipid Research
• Subjects: lipolysis and fatty acid metabolism; insulin resistance; diabetes; fatty acid
• Online Access: http://www.sciencedirect.com/science/article/pii/S0022227520337834

GPR40 and GPR120 are fatty acid sensors that play important roles in glucose and energy homeostasis. GPR40 potentiates glucose-dependent insulin secretion and demonstrated in clinical studies robust glucose lowering in type 2 diabetes. GPR120 improves insulin sensitivity in rodents, albeit its mechanism of action is not fully understood. Here, we postulated that the antidiabetic efficacy of GPR40 could be enhanced by coactivating GPR120. A combination of GPR40 and GPR120 agonists in db/db mice, as well as a single molecule with dual agonist activities, achieved superior glycemic control compared with either monotherapy. Compared with a GPR40 selective agonist, the dual agonist improved insulin sensitivity in ob/ob mice measured by hyperinsulinemic-euglycemic clamp, preserved islet morphology, and increased expression of several key lipolytic genes in adipose tissue of Zucker diabetic fatty rats. Novel insights into the mechanism of action for GPR120 were obtained. Selective GPR120 activation suppressed lipolysis in primary white adipocytes, although this effect was attenuated in adipocytes from obese rats and obese rhesus, and sensitized the antilipolytic effect of insulin in rat and rhesus primary adipocytes. In conclusion, GPR120 agonism enhances insulin action in adipose tissue and yields a synergistic efficacy when combined with GPR40 agonism.